Home » Stocks » DBVT

DBV Technologies S.A. (DBVT)

Stock Price: $5.66 USD 1.92 (51.34%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $5.44 -0.22 (-3.89%) Jan 15, 5:41 PM
Market Cap 407.66M
Revenue (ttm) n/a
Net Income (ttm) -172.57M
Shares Out 30.16M
EPS (ttm) -3.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $5.66
Previous Close $3.74
Change ($) 1.92
Change (%) 51.34%
Day's Open 5.31
Day's Range 4.98 - 5.90
Day's Volume 17,174,176
52-Week Range 1.38 - 12.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 6 hours ago

DBV Technologies (DBVT) stock is soaring higher on Friday after providing an update on its upcoming peanut allergy treatment. The post DBVT Stock: DBV Technologies Soars on Big Peanut Allergy ...

GlobeNewsWire - 1 day ago

Montrouge, France, January 14, 2020

GlobeNewsWire - 1 week ago

Montrouge, France, January 7, 2021

GlobeNewsWire - 1 week ago

Monthly information regarding the total number of voting rights and

GlobeNewsWire - 1 month ago

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

GlobeNewsWire - 1 month ago

Montrouge, France, November 24, 2020

GlobeNewsWire - 2 months ago

Monthly information regarding the total number of voting rights and 

GlobeNewsWire - 2 months ago

Montrouge, France, November 10, 2020 DBV Technologies to Highlight Data on Viaskin ™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

GlobeNewsWire - 2 months ago

Montrouge, France, November 9, 2020 DBV Technologies to Participate in Upcoming Investor Conferences

The Motley Fool - 2 months ago

The company submitted its potential peanut allergy treatment for review in Europe.

24/7 Wall Street - 2 months ago

DBV Technologies S.A. (NASDAQ: DBVT) shares absolutely exploded on Monday after the firm announced that the Marketing Authorization Application (MAA) for its peanut allergy treatment was valid...

GlobeNewsWire - 2 months ago

Montrouge, France, November 2, 2020

GlobeNewsWire - 2 months ago

Montrouge, France, October 30, 2020

GlobeNewsWire - 3 months ago

Monthly information regarding the total number of voting rights and

GlobeNewsWire - 4 months ago

Monthly information regarding the total number of voting rights and 

GlobeNewsWire - 4 months ago

Montrouge, France, September 2, 2020

GlobeNewsWire - 5 months ago

Monthly information regarding the total number of voting rights and 

Market Watch - 5 months ago

Shares of DBV Technologies tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for ...

Business Wire - 5 months ago

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) complied with federal securities laws.

The Motley Fool - 5 months ago

The FDA rejected the company’s application for its peanut-allergy patch.

GlobeNewsWire - 5 months ago

Montrouge, France, August 4, 2020

GlobeNewsWire - 5 months ago

Montrouge, France, July 31, 2020

GlobeNewsWire - 5 months ago

Montrouge, France, July 20, 2020

GlobeNewsWire - 6 months ago

Monthly information regarding the total number of voting rights and 

GlobeNewsWire - 6 months ago

Montrouge, France, July 7, 2020

The Motley Fool - 6 months ago

The company provided a grim business update.

GlobeNewsWire - 6 months ago

Montrouge, France, June 26, 2020

GlobeNewsWire - 7 months ago

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

GlobeNewsWire - 7 months ago

Montrouge, France, June 4, 2020

GlobeNewsWire - 7 months ago

Montrouge, France, June 2, 2020

GlobeNewsWire - 8 months ago

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020

Seeking Alpha - 8 months ago

Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies

Other stocks mentioned: AIMT
GlobeNewsWire - 8 months ago

Montrouge, France, April 30, 2020

GlobeNewsWire - 8 months ago

Montrouge, France, April 20, 2020

The Motley Fool - 8 months ago

DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.

Other stocks mentioned: AIMT
Seeking Alpha - 9 months ago

DBV Technologies: Don't Panic - The Good, The Bad, And The Opportunity

GlobeNewsWire - 9 months ago

Montrouge, France, April 10, 2020

GlobeNewsWire - 9 months ago

Montrouge, France, March 30, 2020

GlobeNewsWire - 9 months ago

Montrouge, France, March 20, 2020

GlobeNewsWire - 9 months ago

                     

GlobeNewsWire - 9 months ago

Montrouge, France, March 16, 2020

GlobeNewsWire - 10 months ago

Montrouge, France, March 4, 2020

GlobeNewsWire - 10 months ago

Montrouge, France, March 4, 2020

GlobeNewsWire - 10 months ago

Montrouge, France, March 2, 2020

GlobeNewsWire - 10 months ago

Montrouge, France, February 24, 2020

GlobeNewsWire - 10 months ago

Montrouge, France, February 21, 2020

GlobeNewsWire - 11 months ago

Montrouge, France, February 10, 2020

GlobeNewsWire - 11 months ago

Monthly information regarding the total number of voting rights and 

GlobeNewsWire - 11 months ago

Montrouge, France, February 6, 2020

GlobeNewsWire - 11 months ago

Montrouge, France, February 4, 2020

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosi... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Daniel Tasse
Employees
311
Stock Exchange
NASDAQ
Ticker Symbol
DBVT
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is 6.76, which is an increase of 19.43% from the latest price.

Price Target
$6.76
(19.43% upside)
Analyst Consensus: Buy